- Mersana Therapeutics ( NASDAQ: MRSN ) has inked a collaboration and licensing agreement with Merck KGaA ( OTCPK:MKGAF ) to develop antibody-drug conjugates against up to two targets.
- Terms call for Merck KGaA ( OTCPK:MKKGY ) to pay a $30M upfront payment. Mersana ( MRSN ) is eligible for up to $800M in royalties as well as tiered royalty payments.
- Mersana's ( MRSN ) ADC platform is designed to generate systemically administered ADCs that locally activate STING signaling in both ?tumor-resident immune cells and in antigen-expressing tumor cells. This pathway can generating innate immune responses that can lead to anti-tumor activity and immunological memory.
- Seeking Alpha's Quant Rating views Mersana ( MRSN ) as a hold with high marks for growth and momentum . ?
For further details see:
Mersana Therapeutics in deal with Merck KGaA for antibody drug conjugates